Maeta M, Koga S, Yoshioka H, Murakami A, Wakatsuki T
Jpn J Surg. 1985 Jul;15(4):318-20. doi: 10.1007/BF02469923.
Four hepatocellular cancer patients and 11 metastatic liver cancer patients were treated with intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) plus 5-fluorouracil. Cis-diamminedichloroplatinum (II) (25-35 mg/m2) was given once a week, 5-fluorouracil (150-180 mg/m2) was infused daily. A partial response was obtained in 3 of 4 patients with primary cancer and in 5 of 9 evaluable metastatic cancer patients; the mean response durations were 27+ weeks in the former and 47+ weeks in the latter. However, severe bone marrow suppression occurred in 4 patients; 3 died of septicemia (2 cases) and massive intra-tracheal bleeding, respectively. This combined intra-hepato-arterial chemotherapy exerts a synergistic anticancer effect on malignant liver tumors, however, the related bone marrow suppression remains to be overcome.
4例肝细胞癌患者和11例转移性肝癌患者接受了肝动脉内输注顺二氯二氨铂(II)加5-氟尿嘧啶的治疗。顺二氯二氨铂(II)(25 - 35mg/m²)每周给药1次,5-氟尿嘧啶(150 - 180mg/m²)每日输注。4例原发性癌症患者中有3例、9例可评估的转移性癌症患者中有5例获得部分缓解;前者的平均缓解持续时间为27 +周,后者为47 +周。然而,4例患者出现了严重的骨髓抑制;3例分别死于败血症(2例)和大量气管内出血。这种联合肝动脉内化疗对恶性肝肿瘤具有协同抗癌作用,然而,相关的骨髓抑制仍有待克服。